Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO4917838 adjunctive therapy in sub-optimally controlled schizophrenia
2010-020718-26Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing RO4917838 plus antipsychotics with Placebo plus antipsychotics (2 arms). Primary endpoints: PANSS positive symptom factor score and PANSS positive symptom factor score in CFHR1-high subgroup. Started Nov 2010; status: completed.
02
Drugs
bitopertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2010-020718-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020718-26.